Impact BioMedical, Inc. Cash Flow Conversion Efficiency
Impact BioMedical, Inc. cash flow conversion efficiency. Based on the latest financial reports, Impact BioMedical, Inc. (IBO) has a cash flow conversion efficiency ratio of 0.225x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.99 Million) by net assets ($-8.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Impact BioMedical, Inc. for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Impact BioMedical, Inc. (2017–2024)
Cash flow conversion efficiency of Impact BioMedical, Inc. from 2017 to 2024. This chart illustrates how Impact BioMedical, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Impact BioMedical, Inc. stock quote for real-time trading data and today's change.
Impact BioMedical, Inc. Cash Flow Conversion Ratio Explained
Impact BioMedical, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Impact BioMedical, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Impact BioMedical, Inc. ranked by their cash flow conversion efficiency. Review free cash flow generation of Impact BioMedical, Inc. to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chosun Welding
KO:120030
|
0.055x |
|
I-Hwa Industrial Co Ltd
TW:1456
|
-0.042x |
|
InkTec Co. Ltd
KQ:049550
|
0.033x |
|
RoboRobo Co. Ltd
KQ:215100
|
0.006x |
|
Forum Markets, Incorporated
NASDAQ:FRMM
|
-0.097x |
|
Aureus Greenway Holdings Inc.
NASDAQ:PUSA
|
0.009x |
|
Public Packages Holdings Bhd
KLSE:8273
|
0.018x |
|
Enwell Energy plc
F:RHN
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Impact BioMedical, Inc. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Impact BioMedical, Inc. from 2017 to 2024. Also see total assets of Impact BioMedical, Inc. for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.24 Million | $-5.64 Million | -0.779x | -671.98% |
| 2023-12-31 | $28.26 Million | $-2.85 Million | -0.101x | +23.95% |
| 2022-12-31 | $32.67 Million | $-4.33 Million | -0.133x | +87.98% |
| 2021-12-31 | $2.94 Million | $-3.25 Million | -1.104x | -610.22% |
| 2020-12-31 | $-5.28K | $-1.14K | 0.216x | +116.83% |
| 2019-12-31 | $94.89K | $-121.98K | -1.286x | -251.97% |
| 2018-12-31 | $197.12K | $-71.99K | -0.365x | +66.34% |
| 2017-12-31 | $295.22K | $-320.34K | -1.085x | -- |
About Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application … Read more